Magnus Financial Group LLC lessened its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) by 56.3% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 14,856 shares of the company's stock after selling 19,125 shares during the quarter. Magnus Financial Group LLC's holdings in Aprea Therapeutics were worth $28,000 at the end of the most recent quarter.
Separately, PDT Partners LLC lifted its holdings in shares of Aprea Therapeutics by 62.5% in the 4th quarter. PDT Partners LLC now owns 142,600 shares of the company's stock worth $409,000 after buying an additional 54,866 shares during the period. 18.95% of the stock is owned by institutional investors and hedge funds.Get Aprea Therapeutics alerts:
Analyst Upgrades and Downgrades
Separately, Wedbush started coverage on Aprea Therapeutics in a research note on Thursday, July 7th. They set an "outperform" rating and a $3.00 price target on the stock.
Aprea Therapeutics Stock PerformanceNASDAQ APRE opened at $0.78 on Friday. The company has a market cap of $18.25 million, a PE ratio of -0.14 and a beta of 0.63. The firm's 50 day moving average price is $0.93 and its 200-day moving average price is $1.24. Aprea Therapeutics, Inc. has a 52-week low of $0.62 and a 52-week high of $5.67.
About Aprea Therapeutics
Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
- Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Want to see what other hedge funds are holding APRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating).
Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.